Today at #Target25, we presented interim clinical data from the phase 2 trial of petosemtamab in combination with standard of care FOLFOX/FOLFIRI in 1L and 2L metastatic colorectal cancer (mCRC) and petosemtamab monotherapy in 3L+ mCRC
#CloseInOnCancer
#ColorectalCancer
ir.merus.nl/news-release...